Structure of Beta-lactam resistance regulators
β-内酰胺耐药调节剂的结构
基本信息
- 批准号:7014710
- 负责人:
- 金额:$ 18.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-01 至 2008-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Staphylococcus aureus is among the most prevalent and antibiotic-resistant of pathogenic bacteria. However, beta-lactam antibiotics, the most effective therapy for treating staphylococcal infections, are becoming less effective as resistance to them among staphylococci increases. Resistance is mediated by a beta-lactamase (encoded by blaZ) that hydrolyzes penicillins and an alternate target, penicillin binding protein (PBP2a, encoded by mecA), to which beta-lactam antibiotics bind poorly. Transcription of mecA and blaZ is activated by signal transduction through either MecRl or BlaRl when the bacterial cell is exposed to an inducing beta-lactam. The mec (MecRI and Mecl) and bla (BlaRl and Blal) regulators seem to have a signal transduction mechanism of action that is unique in prokaryotic biology but its mechanism is unclear, due in part to lack of structural information. Answers to this question not only solve an interesting biological question but may also uncover an induction cascade involving other molecules that could link regulation of P-lactam resistance to essential cellular systems. The major goal of this application is to determine the crystal structures of the multidomain integral membrane MecRl and/or BlaRl proteins that will provide a unique insight into the relationship between the parts of the molecules that are responsible for signal reception and signal transduction. An important long-term objective of this application is to provide a structural framework for understanding the molecular mechanisms involved in antibiotic resistance and the development of novel therapeutics. Moreover, the studies will also provide a wealth of other information, including membrane protein production, solubilization and crystallization techniques that are crucial to the continued understanding of integral membrane proteins. The specific aims are: (1) Structure determination of the intact multidomain BlaRl/MecRl proteins, (2) structure determination of rationally chosen fragments of the BlaRl/MecRl protein, and (3) structure determination of complex between BlaRl/MecRl and their homologous repressers Blal/MecI. The clones and subclones of BlaRl and MecRl will be expressed in E. coli and purified. Crystallization experiments to obtain diffraction-quality crystals using the detergent-micelle, cubic-phase, vesicle-fusion, and bicelle techniques will be undertaken. Subsequently, the structures of the proteins will be determined using X-ray crystallography.
描述(由申请人提供):金黄色葡萄球菌是最普遍,抗生素的致病细菌之一。但是,β-内酰胺抗生素是治疗葡萄球菌感染的最有效疗法,随着葡萄球菌抗性的增加,β-内酰胺抗生素变得越来越有效。电阻是由β-内酰胺酶(由Blaz编码)介导的,该β-内酰胺酶水解青霉素和替代靶标,青霉素结合蛋白(PBP2A,由MECA编码),β-内酰胺抗生素结合不佳。当细菌细胞暴露于诱导的β-内酰胺中时,MECA和BLAZ的转录通过通过MECRL或BLARL的信号转导激活。 MEC(MeCRI和MECL)和BLA(BLARL和BLAL)调节剂似乎具有信号转导的作用机理,该机制在原核生物学中是独一无二的,但其机制尚不清楚,部分原因是缺乏结构信息。这个问题的答案不仅解决了一个有趣的生物学问题,而且还可能揭示涉及其他分子的感应级联,这些分子可以将P-LACTAM耐药性调节与必需细胞系统联系起来。该应用的主要目的是确定多域积分膜MECRL和/或Blarl蛋白的晶体结构,这些膜将对负责信号接收和信号传输的分子部分之间的关系提供独特的见解。该应用的一个重要长期目标是提供一个结构框架,以了解抗生素耐药性和新型治疗剂的发展的分子机制。此外,这些研究还将提供大量其他信息,包括膜蛋白的产生,溶解化和结晶技术,这些技术对于持续了解整体膜蛋白至关重要。具体目的是:(1)完整多域Blarl/MeCRL蛋白的结构确定,(2)(2)结构确定blarl/mecrl蛋白的合理选择的片段,(3)Blarl/mecrl及其同源抑制剂Blal/meci之间的复杂结构确定。 Blarl和Mecrl的克隆和亚克隆将以大肠杆菌表示并纯化。将进行结晶实验,以获得使用洗涤剂 - 薄膜,立方相,囊泡融合和比切尔技术获得衍射质量的晶体。随后,将使用X射线晶体学确定蛋白质的结构。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Martin K Safo其他文献
A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease - <em>In Vivo</em> Efficacy of Ilx-002 in Humanized Mice
- DOI:
10.1182/blood-2024-202714 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
Osheiza Abdulmalik;Kandace Gollomp;Veronica Bochenek;Conroy O Field;Mariana Macias;Benita Balogun;Salma Roland;Martin K Safo;Yan Zhang;Akua Donkor;Abdelsattar Omar;Moustafa El-Araby;David R. Light;Clark Brown;Andrew N Fleischman - 通讯作者:
Andrew N Fleischman
Martin K Safo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Martin K Safo', 18)}}的其他基金
Structure of cytomegalovirus nuclease, UL98
巨细胞病毒核酸酶 UL98 的结构
- 批准号:
8969474 - 财政年份:2015
- 资助金额:
$ 18.63万 - 项目类别:
Structure of cytomegalovirus nuclease, UL98
巨细胞病毒核酸酶 UL98 的结构
- 批准号:
9086246 - 财政年份:2015
- 资助金额:
$ 18.63万 - 项目类别:
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
8776137 - 财政年份:2014
- 资助金额:
$ 18.63万 - 项目类别:
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
9250636 - 财政年份:2014
- 资助金额:
$ 18.63万 - 项目类别:
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
9053281 - 财政年份:2014
- 资助金额:
$ 18.63万 - 项目类别:
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
9445715 - 财政年份:2014
- 资助金额:
$ 18.63万 - 项目类别:
Hemoglobin Modifiers for Sickle Cell Disease Therapy
用于镰状细胞病治疗的血红蛋白调节剂
- 批准号:
9147091 - 财政年份:2014
- 资助金额:
$ 18.63万 - 项目类别:
Rational Design of Novel Estrogen Receptor Antagonists
新型雌激素受体拮抗剂的合理设计
- 批准号:
7174671 - 财政年份:2004
- 资助金额:
$ 18.63万 - 项目类别:
相似国自然基金
金黄色葡萄球菌定植通过同型半胱氨酸-AKT1-S100A8/A9轴促进慢阻肺中性粒细胞炎症及肺功能下降的机制研究
- 批准号:82300059
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
巴氏杀菌乳中金黄色葡萄球菌和肠毒素A风险预测和溯源的人工智能模型构建研究
- 批准号:32302241
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
金黄色葡萄球菌β溶血素抑制巨噬细胞吞噬功能的分子机制研究
- 批准号:82372257
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
Hld促进金黄色葡萄球菌膜泡形成的机制及其在登革热膜泡疫苗制备中的初步应用
- 批准号:82302063
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
TNF-α和IFN-γ协同作用强化金黄色葡萄球菌感染引起的巨噬细胞焦亡和炎症因子风暴的机制研究
- 批准号:32300770
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Creating natural product diversity via the fabrication of a hybrid fatty acid-nonribosomal peptide synthetase
通过制造杂合脂肪酸-非核糖体肽合成酶创造天然产物多样性
- 批准号:
10339399 - 财政年份:2021
- 资助金额:
$ 18.63万 - 项目类别:
Structural and functional characterization of phosphoglycosyl transferases from human pathogens
人类病原体磷酸糖基转移酶的结构和功能表征
- 批准号:
10413360 - 财政年份:2019
- 资助金额:
$ 18.63万 - 项目类别:
Signal Propagation in Protein Allostery: Mechanism and Evolution
蛋白质变构中的信号传播:机制和进化
- 批准号:
9900030 - 财政年份:2019
- 资助金额:
$ 18.63万 - 项目类别:
Discovery and validation of broadly effective LpxH inhibitors as novel therapeutics against multi-drug resistant Gram-negative pathogens
广泛有效的 LpxH 抑制剂的发现和验证作为针对多重耐药革兰氏阴性病原体的新疗法
- 批准号:
10322657 - 财政年份:2019
- 资助金额:
$ 18.63万 - 项目类别:
Signal Propagation in Protein Allostery: Mechanism and Evolution
蛋白质变构中的信号传播:机制和进化
- 批准号:
10326378 - 财政年份:2019
- 资助金额:
$ 18.63万 - 项目类别: